Spain hopes to save 2.4 billion euros by ordering doctors to Rx generics

25 August 2011

As part of moves to reduce the nation’s budget deficit, Spain’s socialist government has passed legislation requiring doctors and pharmacies to prescribe generic drugs rather than the more expensive brand names sold by pharmaceutical companies, with the aim of generating savings of 2.4 billion euros ($3.46 billion) a year.

Commenting on the move, Prime Minister Jose Luis Zapatero said the law would help Spain continue to lower the state's drug bill, which has already fallen 10% this year, due in part to measures introduced to increase the use of generic products, as well as swinging drug price cuts of as much as 23% introduced last year that were expected to result in savings of 1.3 billion euros (The Pharma Letter May 17, 2010).

According to a report in the UK’s Guardian, Spanish doctors will now have to write only the name of the active ingredients of the medicine they are prescribing for their patients, as well as the dose and format. The drugs are paid for partly by the state and partly by patients. Pharmacies will be obliged to provide the cheapest available versions of drugs, which will frequently mean not the better-known brand names sold by the big drugs firms.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics